Education
About Us
Working with TipRanks
Follow Us
Ensysce Biosciences (ENSC)
NASDAQ:ENSC
ENSC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.62 - $14.68
Previous CloseN/A
Volume52.20K
Average Volume (3M)194.42K
Market Cap
$5.00M
Enterprise Value$2.21M
Total Cash (Recent Filing)$3.05M
Total Debt (Recent Filing)$257.38K
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Aug 19, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding2,370,698
10 Day Avg. Volume123,342
30 Day Avg. Volume194,418
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.97
Price to Sales (P/S)0.00
P/FCF Ratio-0.86
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue0.31
Enterprise Value/Gross Profit2.18
Enterprise Value/Ebitda-0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ensysce Biosciences News
PremiumCompany Announcements
Ensysce Biosciences Advances in Pain Relief Innovation
PremiumMarket News
3 Penny Stocks to Watch Now, 4/24/25
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.36% Mutual Funds
14.82% Other Institutional Investors
84.77% Public Companies and Individual Investors
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $1.62 and its highest was $14.68 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Ensysce Biosciences’s market cap is $5.00M.
When is Ensysce Biosciences’s upcoming earnings report date?
Ensysce Biosciences’s upcoming earnings report date is Aug 19, 2025 which is in 32 days.
How were Ensysce Biosciences’s earnings last quarter?
Ensysce Biosciences released its earnings results on May 13, 2025. The company reported -$1.39 earnings per share for the quarter, beating the consensus estimate of -$3.015 by $1.625.
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Overvalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate is -1.02.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 2,370,698 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Ensysce Biosciences reported an EPS of -$1.39 in its last earnings report, beating expectations of -$3.015. Following the earnings report the stock price went up 11.594%.
Which hedge fund is a major shareholder of Ensysce Biosciences?
Currently, no hedge funds are holding shares in ENSC
Company Description
Ensysce Biosciences
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Technical Analysis
Galmed Pharmaceuticals
―
Aptevo Therapeutics
―
Enveric Biosciences
―
Revelation Biosciences
―
Tao Synergies
―